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Background: Scattered radiation can be assessed by in vivo dosimetry. Thyroid tissue is sensitive to radiation, even
at doses <10 cGy. This study compared the scattered dose to the thyroid measured by thermoluminescent
dosimeters (TLDs) and the estimated one by treatment planning system (TPS).
Methods: During radiotherapy to sites other than the thyroid of 16 children and adolescents, seventy-two TLD
measurements at the thyroid were compared with TPS estimation.
Results: The overall TPS/TLD bias was 1.02 (95% LA 0.05 to 21.09). When bias was stratified by treatment field, the
TPS overestimated TLD values at doses <1 cGy and underestimated them at doses >10 cGy. The greatest bias was
found in pelvis and abdomen: 15.01 (95% LA 9.16 to 24.61) and 5.12 (95% LA 3.04 to 8.63) respectively. There was
good agreement in orbit, head, and spine: bias 1.52 (95% LA 0.48 to 4.79), 0.44 (95% LA 0.11 to 1.82) and 0.83 (0.39
to 1.76) respectively. There was small agreement with broad limits for lung and mediastinum: 1.13 (95% LA 0.03 to
40.90) and 0.39 (95% LA 0.02 to 7.14) respectively.
Conclusions: The scattered dose can be measured with TLDs, and TPS algorithms for outside structures should be
improved.
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The effects of ionizing radiation on the thyroid gland
have been studied for decades [1,2] and the association
between hypothyroidism, hyperthyroidism, thyroid nod-
ules, thyroid cancer and radiation is often reported [3,4].
Nevertheless, the thresholds of absorbed dose, the mech-
anism of injury, and related risk factors have not been
clearly established and necessitate further research. The
thyroid is particularly sensitive to radiation and may
be directly or indirectly exposed to it during radiation
therapy of other organs [5]. Doses as low as 10 cGy are
known to be associated with an increased incidence of
thyroid nodules and thyroid cancer [6,7].* Correspondence: rhelnecave@gmail.com
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stated.Children are more sensitive to injury caused by ioniz-
ing radiation, due to their greater rate of cell replication
and to their longer life expectancy. Furthermore, the
distances between body segments in relation to the site
of irradiation are smaller in children. Even the most
modern radiation therapy will cause incidental exposure
of nontarget tissues and organs. Dosimetry studies have
shown that radiation scatters to the thyroid gland [8,9].
Knowing the radiation dose that reaches healthy tis-
sues plays a key role in determining clinical effects over
time and establishing respective tolerance doses. Older
data on damage to normal tissues by radiation therapy
were based on retrospective studies or on the clinical
experience of radiation therapists [10]. Modern com-
puted tomography (CT)-assisted techniques for planning
of three-dimensional conformal radiation therapy enable
mathematical estimation of the radiation dose scattered
to healthy tissues near the target field during treatment,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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irradiated organ. The Quantitative Analysis of Normal
Tissue Effects in the Clinic (QUANTEC) study pro-
vided information on dose, volume, and prognosis for
different organs, including – more recently – the thy-
roid gland, while taking into account the development
of hypothyroidism [11,12]. A retrospective study of pa-
tients with Hodgkin lymphoma showed that thyroid vol-
ume percentages in excess of 10, 20, and 30 Gy (V10, V20,
and V30) were significantly associated with hypothyroidism
at mean doses of 32 Gy. Thyroid V30 was an independent
predictor of the risk of hypothyroidism [13].
The dosimetric accuracy of radiation therapy can be mea-
sured by means of in phantom or in vivo dosimetry [14].
Among the various techniques available for absolute dosim-
etry, thermoluminescent dosimeters (TLDs) have been
widely used for their simplicity, excellent spatial resolution,
and ability to integrate the dose absorbed over a certain
period of time [15]. TLDs can be used on the body surface
or within body cavities. Most studies that use TLDs focus
on quantification of the main beam dose, and scattered
dose studies are usually performed in phantoms, not
in vivo [16]. In the present study, we evaluated the
agreement between scattered radiation dose to the thy-
roid as predicted by a treatment planning system (TPS)
for three-dimensional conformal radiation therapy and
that measured by TLDs placed on the skin overlying
the thyroid region in a sample of children treated for a
variety of non-thyroid cancers.
Methods
Sample
Sixteen patients with a mean age of 6.99 years (range
1.3–17.7 years) received radiation therapy for a variety
of non-thyroid cancers in several regions of the body.
Treatments were administered with two linear accelera-
tors: a Siemens Mevatron MD (SN 3054, nominal pho-
ton energy 6 MV) and a Varian 23EX (SN 3595, nominal
energy 6 and 15 MV) at the radiation therapy center of a
large tertiary care hospital.
Skin entrance radiation doses at the thyroid region were
measured with TLDs. The dosimeters were Harshaw TLD-
100 (Thermo RMP) chips (lithium fluoride doped
with magnesium and titanium [LiF:MgTi], dimensions:
3×3×0.9 mm3). Eleven patients also underwent three-
dimensional radiation therapy planning in which the
thyroid region was included in the planning CT scan
volume, thus enabling estimation of doses scattered to
the gland during treatment. Doses measured by the
TLDs were then compared with the estimates pro-
duced by the TPS mathematical model.
The sample comprised 16 patients, from whom 102
scattered dose measurements were obtained by TLDs
and 72 paired dose estimates were calculated by TPS. Atotal of 72 measurements were used in this comparison,
as five patients either did not undergo CT-based treat-
ment planning or did not have the thyroid gland in-
cluded in their scans.In vivo dosimetry
During treatment, TLDs were placed onto the skin over-
lying the thyroid isthmus and measured the scattered
radiation from each treatment field that reached the thy-
roid gland. As the thyroid is located only a few millime-
ters from the surface (skin), one may estimate that the
entrance dose (by definition, the absorbed dose at depth
of maximum ionization) is the dose absorbed by the
gland. Therefore, doses measured by TLDs during treat-
ment provide reliable estimates of the radiation dose
deposited in the region of the gland. At least two mea-
surements were obtained for each treatment field.
TLDs were provided and analyzed by the Radiation
Therapy Quality Program of the Brazilian National
Cancer Institute (INCA) in Rio de Janeiro. One pair of
TLDs was used for each treatment field, and the mean
of two measured values calculated for analysis. The pair
of TLDs was placed into a chrome-nickel steel hemi-
spherical build-up cap (radius 15 mm) to accomplish
electronic equilibrium and to ensure maximal readings.
Determination of the dose absorbed into TLDs took into
account background radiation (BG), the dose linearity cor-
rection factor (klin), and the calibration coefficient (CC) of
the TLDs employed, as this was a relative dosimetry system
—i.e. doses were obtained by comparison between the TLD
and a TLD exposed to a known radiation dose under refer-
ence conditions. The energy dependence of TLDs could be
neglected, since all measurements were obtained at the
same energy of dosimeter calibration. The fading effect was
also not taken into account, as all dosimeters were irradi-
ated and read together on the same day.
Under reference conditions for TLD irradiation, the
absorbed dose used in the experimental array was 40 cGy.
TLDs were placed between two 5 cm-thick acrylic slabs (as
a phantom to simulate body mass), at center beam, with a
distance of 100 cm between the radiation source and the
surface, a (10×10) cm2 field, a dose rate of 200 MU/min,
and a nominal energy of 6 MV.
TLDs were calibrated by adjusting the measurements
in thermoluminescent (TL) signal with the doses pro-
vided by the linear accelerator, taking into account a
dose of 40 cGy (the reference dose, Dref ), which was the
most expected for the majority of patients. To deliver
this dose, the accelerator was set to 164 MU.
The linear accelerator was calibrated with a Farmer-
type ionization chamber (PTW TN30004, S/N 244) and
a PTW Unidos E electrometer (S/N T10010-00055), in
accordance with the IAEA TRS-398 protocol.
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at the Radiation Therapy Quality Program, INCA, Rio de
Janeiro. Annealing was performed with an EDG1800 oven
(EDG Equipamentos, Brazil) and a Fanem 315SE drying
oven (Fanem, Brazil).
Dose counts are shown in the reader as a TL signal
and then converted to an absorbed dose unit (cGy). This
value is then multiplied by the calibration coefficient
after subtracting the background radiation (BG).





The uncorrected dose (Duncorr) is the uncorrected dose
at the measurement TLD, as per Equation 2:
Duncorr ¼ CC TL ¼ BGð Þ ð2Þ
To correct for nonlinear dose–response, a linearity cor-
rection curve was plotted for the radiation beam (Figure 1),
using 15 pairs of TLDs in the same experimental array used
for irradiation of the calibration TLDs.
Three pairs of TLDs were used for each of the five known
doses: 10, 20, 35, 50, and 85 cGy. These doses were chosen
in view of the expected doses for the type of treatment used
in the study sample. The vertical axis in Figure 1 represents
the correction factor for nonlinearity (klin).
The determining points (klin) of the best-fit curve for
correction of nonlinearity were calculated using Equa-
tion 3 where M is the TLD readout (or TL signal), D is
the absorbed dose, and parameters with an index of zero






(3)Figure 1 Linearity coefficient of TLD measurements. Linearity coefficienFinally, the patient – or corrected – dose (Duncorr) was
calculated by the aforementioned factors (Equation 4):
Computerized planning of 3D conformal radiation
therapy.
In patients who underwent computerized planning of 3D
conformal radiation therapy, a radiologist singled out the
thyroid gland in their planning CT scans. The estimated
scattered dose to the thyroid during radiation therapy was
then calculated with the Eclipse 10.0 TPS (VARIAN
Medical Systems, USA). The software package used
anisotropic analytical algorithms for dose calculation.
Scattered doses to the thyroid gland and to the skin
overlying the thyroid isthmus, where TLDs were placed,
were estimated in the TPS. Field and total radiation
doses were calculated. Dose-volume histograms were
used to determine the minimum, mean, and maximum
dose to the gland, and the mean dose was used for stat-
istical analyses.
The distance between the skin overlying the thyroid isth-
mus to the treatment field hot spot was also measured.
In two patients who received spinal irradiation, part of
the main beam dose also contributed to the measured
doses.
The procedures carried out with the patients in this
study were reviewed and approved by the Research
Ethics Committee of the institution where the study was
conducted, in accordance with standards set by the
committee and in compliance with the 1975 Helsinki
Declaration and its 2000 revision. Assent from patients
and informed consent from their legal guardians was
obtained before the study.
Statistical analysis
This was a cross-sectional study based on a sample of
children and adolescents who underwent treatment at
(4)t of TLD values as a function of absorbed dose in the acrylic phantom.
Figure 2 Scatter plot of correlation between TLD and TPS
[skin]-estimated doses. Scatterplot of relationship between
TPSskin and TLD values. r: Pearson correlation coefficient; p: statistical
significance.
Table 1 Sample profile
Variable n = 16




Cancer type, n (%)
Adrenal neuroblastoma 3 (18.8)
Acute lymphoblastic leukemia 2 (12.5)
Retinoblastoma 2 (12.5)
Wilms’ tumor 2 (12.5)
Acute myeloid leukemia 1 (6.3)
Hodgkin’s lymphoma 1 (6.3)
Non-Hodgkin lymphoma 1 (6.3)
Medulloblastoma 1 (6.3)
Mediastinal neuroblastoma 1 (6.3)
Rhabdomyosarcoma 1 (6.3)
CNS tumor 1 (6.3)




Head and spine 2 (12.5)
Orbit 2 (12.5)




Thyroid–hot spot distance, cm 14 (4–27)
Total prescribed dose, cGy 3600 (1350–14400)




Scattered dose to the thyroid (TLD), cGy 283 (1–6754)
Data are expressed as n (%) or median (range).
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hospital. The sample comprised 16 patients, from whom
102 scattered dose measurements were obtained by TLDs
and 72 paired dose estimates were calculated by TPS. This
number is within the range suggested by Altman [17]
and Bland, [18] who propose that 50 to 100 observa-
tions are required to measure agreement in method
comparison studies.
Normally distributed quantitative data were expressed
as means and standard deviations. Skewed data wereexpressed as medians and ranges, and categorical data,
as counts and percentages.
To evaluate the difference between TPS estimates of
radiation scattered to the thyroid gland (TPSthyroid)
and to the point of skin overlying the thyroid isthmus
(TPSskin), where the TLDs were placed, data were log-
transformed to reduce asymmetry. Groups were then
compared using a linear mixed effects model, which
takes into account the fact that repeated observations
are available for each patient.
To assess the correlation between TPSskin and TLD,
Pearson correlation coefficients were calculated for the
log-transformed measurements using a mixed model.
Due to the known limitations of the Pearson correlation
coefficient for analysis of agreement, we chose to use
the Bland–Altman method to compare actual TLD-
measured doses of radiation and TPSskin estimates. As
TPSskin and TLD values were asymmetrically distributed,
we chose to use TPSskin/TLD ratios as an alternative to log-
arithms [19]. Furthermore, only TLD measurements rather
than the mean of TPSskin and TLD measurements were
plotted onto the x-axis, as recommended when one of the
methods under study is considered the gold standard [19].
Results were then plotted on log scale to facilitate
visualization of the calculated values. Repeated measures
were clustered by patient and analyzed with a mixed effects
model, which estimated bias values (mean difference be-
tween ratios for each method) and 95% limits of agreement
(95% LA).
To assess the impact of prescribed radiation dose and
TLD–hot spot distance on TLD measurements, data were
log-transformed (to reduce asymmetry), z scores were cal-
culated (to standardize units), and a mixed model was used
for analysis.
Figure 3 (See legend on next page.)
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Figure 3 Bland–Altman plots of agreement between TLD and TPS measurements. Bland–Altman plots of overall agreement between
TPSskin and TLD measurements, stratified by specific anatomical site (dark points): (A) Overall agreement (bias, 1.02; 95% LA, 0.5 to 21.09); (B)
Pelvis (bias, 15.01; 95% LA, 9.16 to 24.61); (C) Abdomen (bias, 5.12; 95% LA, 3.04 to 8.63); (D) Orbit (bias, 1.52; 95% LA, 0.48 to 4.79); (E) Head (bias,
0.44; 95% LA, 0.11 to 1.82); (F) Lung (bias, 1.13; 95% LA, 0.03 to 40.90); (G) Mediastinum (bias, 0.39; 95% LA, 0.2 to 7.14); (H) Spine (bias, 0.83;
95% LA, 0.39 to 1.76).
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processed and analyzed in the SPSS 18.0, R 2.14.1 and
SigmaPlot 11.0 software environments.
Results
The sample profile is shown in Table 1. Comparison be-
tween TPSthyroid and TPSskin values did not reach statis-
tical significance (P = 0.842). Therefore, TPSskin was
considered appropriate for comparison with actual TLD-
measured doses.
There was a significant correlation between the TLD-
measured dose and the TPSskin-estimated dose (r = 0.94,
P < 0.001) (Figure 2).
Analysis of Bland-Altman plots for the TPSskin/TLD
ratio at different levels of radiation showed that the bias
of the TPS/TLD ratio behaved differently in relation to
TLD-measured doses. Below 1 cGy, the TPS overesti-
mated the actual dose, as measured by TLDs (Figure 3).
Between 1 and 10 cGy, the bias ranged around 1, show-
ing agreement between the two methods. Above 10 cGy,
the TPS was more likely to underestimate the scattered
dose as compared with actual TLD measurements.
Although the overall bias was small (bias = 1.02), the
95% limits of agreement were broad (95% LA: 0.05 to
21.09). Analysis by site of irradiation showed different
TPS/TLD biases according to the proximity of the thy-
roid gland to the treatment field.
Figures 3 and 4 show dose behavior by site of irradi-
ation. The dose scattered to the thyroid was <0.1 cGyFigure 4 Limits of agreement for TPS[skin]/TLD ratios by
anatomical site. 95 % limits of agreement for TPSskin/TLD ratios, by
anatomical site. MDT, mediastinum; ABD, abdomen; PLV, pelvis.when the pelvis or abdomen were irradiated. The TPS
overestimated the scattered dose, and there was little
agreement between TPS and TLD measurements—bias
of 15.01 (95% LA 9.16 to 24.61) and 5.12 (95% LA 3.04
to 8.63) respectively (Figure 3B and 3C).
The TPS and TLDs provided similar measurements
of radiation scattered to the thyroid when the site of ir-
radiation was the orbit, head, or spine, with biases of
1.52 (95% LA 0.48 to 4.79), 0.44 (95% LA 0.11 to 1.82),
and 0.83 (95% LA 0.39 to 1.76) respectively (Figure 3D,
3E and 3H).
When the lungs or mediastinum were irradiated, TPS
estimates and TLD measurements behaved in a similar
fashion, with broad limits of agreement and a bias of
1.13 (95% LA 0.03 to 40.90) and 0.39 (95% LA 0.02 to
7.14) respectively (Figure 3F and 3G). At doses >10 cGy,
the TPS underestimated the scattered dose up to tenfold
as compared to TLD-measured values.
The TLD detected irradiation of the thyroid region
even in patients in whom no TPS had been used and
whose treatment site was remote from the thyroid.
The distance between the skin overlying the thyroid
isthmus to the treatment field hot spot of radiation
therapy had a greater impact on TLD measurements
(b=−2.26; P < 0.001) than prescribed dose (b = 1.26; P <
0.001), although the two impacts were independent.
Discussion
Most dosimetry studies on scattered dose to the thyroid
gland are performed in phantom, and are thus retro-
spective simulations of radiation therapy [8,20]. A previ-
ous study conducted in vivo dosimetry of the scattered
dose to the thyroid using TLDs on adult patients under-
going radiation therapy for breast cancer [21]. In the
present study, measurements were obtained in children
and adolescents who were receiving radiation for cancers
at a variety of sites, with different doses, at different dis-
tances from the thyroid. There was significant scatter of
radiation to the thyroid gland, even when treatment was
targeted at different organs, in different locations, that
did not include the thyroid in the treatment field.
TPSs are commonly used to estimate the dose scat-
tered to non-target organs, such as the thyroid gland.
We demonstrated that the scattered dose can in fact
be measured with TLDs, since we did not find any
difference between dose measurements on the skin and
TPS-based estimation of doses within the gland. At sites
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measurements, such as the orbit, head, and spine, TPS
estimates are quite reasonable. However, at more remote
locations, such as the abdomen and pelvis, the TPS over-
estimated the scattered dose as compared with actual
doses measured by TLDs. The algorithms used for TPS
dose estimation are developed for calculation of radi-
ation doses within the treatment field—in fact, only a
few centimeters from the field edges—, which also may
have influenced bias findings. More elaborate simula-
tions are required to calculate doses to proximal or
distal tissues of interest regarding varying volume and
density of tissues, solid structures and air cavities. In
vivo dosimetry may add information for algorithm calcu-
lations, even considering tissue heterogeneity and other
biases.
Agreement was low and the limits of agreement broad
for the lung and mediastinum because the thyroid was
too close to the dosimetric penumbra zone, that is, the
edges of the treatment field, where the irradiated dose is
20% to 80% of the prescribed dose at the central axis.
Even when the thyroid was farther from the irradiation
field, TLDs measured doses that although small were
enough to cause injuring in children and adolescents.
Doses as low as 10 cGy are associated with thyroid nod-
ules and cancer [6]. In children, the distance between
body segments and the irradiation field is smaller, in-
creasing the scattered radiation to the thyroid gland.
Our study showed that the distance from the thyroid to the
treatment field hot spot has a greater impact than pre-
scribed dose on TLD measurements, although the two im-
pacts were independent. Considering the heterogeneity
among the subjects studied, a larger sample would add to
the accuracy of the findings.Conclusions
Any exposure of the thyroid gland to radiation is cause
for concern, particularly in children. In vivo dosimetry
plays an important role in the characterization of
hazardous exposure with respect to dose escalation. As
TPSs are constructed with algorithms that have treat-
ment as their objective, correction of mathematical co-
efficients for the estimated dose that reaches major
structures outside the main treatment field may be en-
hanced with the knowledge obtained from in vivo dos-
imetry. TLDs and TPS exhibit excellent agreement
with radiation doses at the central-axis position, but
further studies are required to determine their behav-
ior for different energy peaks outside the central axis.
Future studies using in vivo TLD dosimetry should be
conducted to determine the actual radiation reaching
tissues and organs far from the field treated during
radiotherapy.Abbreviations
TLDs: Thermoluminescent dosimeters; TPS: Treatment planning system;
CT: Computed tomography; CC: Calibration coefficient; BG: Background dose.
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